We are currently experiencing technical issues due to the Microsoft outage. This will affect delivery of multi-factor authentication emails, invoice emails and service emails. We apologise for the disruption.

Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesSpringWorks Therapeutics Inc

SpringWorks Therapeutics Inc

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
None USD 0.00(0%)
Last update at 2025-07-30T13:05:02.506751Z
Market Cap
3134.60M

Momentum Score

…

SpringWorks Therapeutics, Inc., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is OGSIVEO (nirogacestat), an oral small molecule gamma secretase inhibitor that is in Phase III DeFi trial for the treatment of desmoid tumors; and Nirogacestat, is also in Phase 2 clinical development as a monotherapy for the treatment of ovarian granulosa cell tumors (GCT), a subtype of ovarian cancer. The company is also involved in the development of mirdametinib, an oral small molecule MEK inhibitor that is in Phase 2b clinical trials for the treatment of neurofibromatosis type 1-associated plexiform neurofibromas (NF1-PN); mirdametinib + lifirafenib, a combination therapy that is in Phase 1b clinical trial in patients with advanced or refractory solid tumors; and mirdametinib in monotherapy and combination approaches to treat other genetically defined solid tumors, including Phase 1/2 clinical trial for the treatment of pediatric and young adult patients with low-grade gliomas. In addition, it develops Brimarafenib (BGB-3245), an oral selective small molecule inhibitor of monomeric and dimeric forms of activating BRAF mutations. The company has collaborations with BeiGene, Ltd. and GlaxoSmithKline LLC; and license agreements with Pfizer Inc. for nirogacestat and mirdametinib. It also has a license agreement with Katholieke Universiteit Leuven and the Flanders Institute for Biotechnology for a portfolio of novel small molecule inhibitors of the TEA Domain; and Dana-Farber Cancer Institute for a portfolio of novel small molecule inhibitors of Epidermal Growth Factor Receptor. The company was founded in 2017 and is headquartered in Stamford, Connecticut.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

52 Week Price Range
18.00
Low
53.92
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High

Key Metrics*

Previous Close
-
Dividend Yield
-
Revenue TTM
26.45M
Revenue Per Share
0.40
Gross Profit TTM
35.00M
Debt / Equity
0.01
ROE
-63.12%
Net Debt
-169.00M
ROCE
-43.46%
Diluted EPS TTM
-5.15

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax -277.42M -173.91M -45.57M -58.31M -17.81M
Net income -274.16M -173.21M -44.24M -54.76M -17.81M
Selling general administrative 134.55M 71.79M 29.46M 16.69M 8.59M
Gross profit 6.15M - 35.00M - -
Reconciled depreciation 0.77M 0.49M 0.35M 0.19M 0.02M
Ebit -281.44M -173.47M -46.32M -59.24M -18.49M
Ebitda -280.67M -172.98M -45.98M -59.05M -18.47M
Depreciation and amortization 0.77M 0.49M 0.35M 0.19M 0.02M
Operating income -280.67M -173.47M -46.32M -59.24M -18.49M
Other operating expenses 280.67M 173.47M 81.32M 59.24M 18.49M
Interest expense -0.77M 0.44M 0.00M 0.00M 0.00M
Interest income 6.29M 0.70M 1.33M 3.55M 0.68M
Net interest income 6.29M 0.70M 1.33M 3.55M 0.68M
Income tax expense -3.26M -0.70M -1.33M -3.55M 0.68M
Total revenue 6.15M 0.00M 35.00M 0.00M 0.00M
Total operating expenses 280.67M 173.47M 81.32M 59.24M 18.49M
Total other income expense net 3.26M -0.44M 0.75M 0.93M 0.68M
Net income from continuing ops -277.42M -173.91M -45.57M -58.31M -17.81M
Net income applicable to common shares -277.42M -173.91M -45.57M -50.58M -17.81M
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 725.79M 630.24M 452.49M 576.19M 334.83M
Intangible assets 11.20M - - - -
Other current assets 12.68M 7.55M 9.41M 4.91M 3.71M
Total liab 99.57M 72.05M 30.10M 19.13M 12.76M
Total stockholder equity 626.22M -569.93M 422.40M 557.06M 322.07M
Deferred long term liab - - - - 0.70M
Other current liab 65.57M 39.24M 25.38M 14.88M 9.32M
Common stock 0.01M 0.01M 0.01M 0.01M 0.00M
Capital stock 0.01M 0.01M 0.01M 0.01M 0.00M
Retained earnings -895.03M -569.93M -292.51M -118.60M -73.03M
Other liab - 16.23M - 0.16M 0.79M
Other assets - 3.23M 3.27M 2.57M 1.70M
Cash 176.05M 67.49M 103.96M 147.09M 327.65M
Total current liabilities 78.17M 51.05M 29.97M 17.61M 11.97M
Current deferred revenue 4.14M 3.31M - - -
Net debt -169.00M -62.24M -102.67M -144.35M -327.65M
Short term debt 1.06M 0.48M 1.16M 1.38M -
Short long term debt total 7.06M 5.25M 1.29M 2.73M -
Other stockholder equity 1520.06M 0.76M 715.22M 675.62M 395.10M
Property plant equipment - 18.27M 4.20M 3.02M 0.80M
Total current assets 500.91M 599.76M 382.91M 513.40M 331.36M
Long term investments 185.34M 8.99M 62.11M 57.21M 0.98M
Net tangible assets - 558.19M 422.40M 557.06M 322.07M
Short term investments 303.15M 524.72M 269.54M 361.39M -
Net receivables 5.93M - - - -
Inventory 3.10M - - - -
Accounts payable 7.40M 8.01M 3.43M 1.35M 2.65M
Accumulated other comprehensive income 1.19M -0.77M -0.31M 0.04M -334.83M
Common stock total equity - - - 0.01M 0.00M
Non currrent assets other 4.25M 3.23M 3.27M 2.57M 1.70M
Non current assets total 224.88M 30.48M 69.58M 62.79M 3.47M
Capital lease obligations 7.06M 5.25M 1.29M 2.73M -
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments -215.60M 85.61M -418.83M -4.26M -0.29M
Change to liabilities 23.71M 2.07M -1.30M 1.88M 0.49M
Total cashflows from investing activities -215.60M 83.59M -418.83M -4.26M -0.29M
Total cash from financing activities 340.70M 1.16M 270.49M 333.71M 50.38M
Change to operating activities 14.39M 3.04M 2.65M 3.07M 2.07M
Net income -277.42M -173.91M -45.57M -58.31M -17.81M
Change in cash -36.46M -43.13M -180.54M 282.00M 35.38M
Begin period cash flow 104.53M 147.65M 328.19M 46.19M 10.27M
End period cash flow 68.07M 104.53M 147.65M 328.19M 45.65M
Total cash from operating activities -161.56M -127.88M -32.19M -47.44M -14.71M
Issuance of capital stock 340.07M 0.00M 269.59M 333.69M 50.38M
Depreciation 0.77M 0.49M 0.35M 0.19M 0.02M
Other cashflows from investing activities - - - -3.59M -
Sale purchase of stock -1.34M - - 333.71M 50.38M
Other cashflows from financing activities 1.98M 1.16M 0.89M 163.98M 50.38M
Change to netincome 76.99M 40.42M 11.69M 5.72M 1.07M
Capital expenditures 10.20M 2.02M 0.64M 0.67M 0.29M
Change in working capital 38.10M 5.12M 1.35M 4.95M 2.02M
Stock based compensation 72.97M 38.44M 10.03M 3.11M 1.07M
Other non cash items 4.02M 0.99M 1.05M 2.61M -
Free cash flow -171.76M -129.89M -32.83M -48.11M -15.00M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
NVO
Novo Nordisk A/S		 -0.54
1.32%		 40.55 41.58 31.15 2.13 32.99 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 -2.37
0.43%		 544.66 30.22 24.27 10.36 6.50 9.99 24.66
REGN
Regeneron Pharmaceuticals Inc		 -2.77
0.29%		 956.64 29.07 20.12 7.57 3.82 6.95 19.42
ARGNF
argenx SE		 -
-%		 900.30 45.77 31.25 13.84 7.12 11.38 36.06

Profile*

SpringWorks Therapeutics Inc

SpringWorks Therapeutics, Inc., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is OGSIVEO (nirogacestat), an oral small molecule gamma secretase inhibitor that is in Phase III DeFi trial for the treatment of desmoid tumors; and Nirogacestat, is also in Phase 2 clinical development as a monotherapy for the treatment of ovarian granulosa cell tumors (GCT), a subtype of ovarian cancer. The company is also involved in the development of mirdametinib, an oral small molecule MEK inhibitor that is in Phase 2b clinical trials for the treatment of neurofibromatosis type 1-associated plexiform neurofibromas (NF1-PN); mirdametinib + lifirafenib, a combination therapy that is in Phase 1b clinical trial in patients with advanced or refractory solid tumors; and mirdametinib in monotherapy and combination approaches to treat other genetically defined solid tumors, including Phase 1/2 clinical trial for the treatment of pediatric and young adult patients with low-grade gliomas. In addition, it develops Brimarafenib (BGB-3245), an oral selective small molecule inhibitor of monomeric and dimeric forms of activating BRAF mutations. The company has collaborations with BeiGene, Ltd. and GlaxoSmithKline LLC; and license agreements with Pfizer Inc. for nirogacestat and mirdametinib. It also has a license agreement with Katholieke Universiteit Leuven and the Flanders Institute for Biotechnology for a portfolio of novel small molecule inhibitors of the TEA Domain; and Dana-Farber Cancer Institute for a portfolio of novel small molecule inhibitors of Epidermal Growth Factor Receptor. The company was founded in 2017 and is headquartered in Stamford, Connecticut.

100 Washington Boulevard, Stamford, CT, United States, 06902

203 883 9490

https://www.springworkstx.com

305

Name Title Year Born
Mr. Saqib Islam J.D. CEO & Director 1970
Mr. Francis I. Perier Jr., M.B.A. Chief Financial Officer 1960
Dr. Badreddin Edris Ph.D. Chief Operating Officer 1987
Mr. Bhavesh Ashar Chief Commercial Officer 1966
Mr. Michael P. Nofi Chief Accounting Officer 1971
Ms. Kim Diamond VP of Communications & Investor Relations NA
Mr. Herschel S. Weinstein J.D. Gen. Counsel & Sec. 1956
Mr. Daniel J. Pichl Chief People Officer 1983
Dr. L. Mary Smith PH.D. Chief Devel. Officer 1967
Dr. James Cassidy M.D., Ph.D. Chief Medical Officer NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

CJT
CAD 111.15
+12.71%
CLS
CAD 374.20
+8.33%
GRZ
CAD 4.90
+7.46%
CTC-A
CAD 218.05
+6.38%
FEC
CAD 7.42
+5.85%
TF
CAD 4.13
-19.65%
TLO
CAD 5.98
-15.06%
FSZ
CAD 2.45
-14.04%
XNDU
CAD 3.60
-8.86%
ITR
CAD 2.75
-8.50%

Equity Sectors*

  • Basic Materials

    -2.63%

  • Communication Services

    -0.79%

  • Consumer Cyclical

    +0.08%

  • Consumer Defensive

    -0.12%

  • Energy

    +0.52%

  • Financial Services

    -1.15%

  • Healthcare

    -1.74%

  • Industrials

    -0.64%

  • Real Estate

    -0.12%

  • Technology

    -0.51%

  • Utilities

    -0.02%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…